Halozyme Therapeutics, Inc.

Unlock to Claim this listing
Add / Modify Company

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody.

Click to rate this company
[Total: 0 Average: 0]

3.2

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Through a strategic lens of environmental responsibility, Halozyme Therapeutics acknowledges its role in minimizing ecological impact by actively integrating sustainable practices throughout its operational landscape, encompassing energy-efficient facilities, responsible waste management, and resource optimization, all underscored by a steadfast commitment to reducing its carbon footprint and promoting the efficient use of natural resources in alignment with its mission to contribute to a healthier planet for present and future generations.Halozyme Therapeutics stands as an exemplar of positive social impact, driven by its unwavering dedication to addressing critical healthcare needs and improving patient well-being on a global scale, channeling its innovative therapies and scientific advancements toward the betterment of human health, while actively engaging in patient advocacy, community partnerships, and health education initiatives, thereby fostering a collective sense of empowerment, inclusivity, and hope within the communities it serves.At the heart of its corporate ethos lies Halozyme Therapeutics’ steadfast commitment to exemplary governance practices that prioritize transparency, accountability, and ethical conduct across its operations, reinforced by a diverse and experienced board of directors, rigorous compliance measures, and a culture of integrity that permeates its decision-making processes, ensuring a harmonious alignment between stakeholder interests, corporate values, and regulatory requirements. Halozyme Therapeutics’ commitment to research excellence and innovation is a driving force behind its ESG sustainability strategy, characterized by its dedication to advancing groundbreaking therapies that address unmet medical needs, improve patient outcomes, and contribute to the evolution of medical science, all while adhering to the highest standards of research ethics, clinical integrity, and patient safety.Halozyme Therapeutics’ financial sustainability is intricately interwoven with its broader ESG commitments, as its financial success is inextricably linked to its ability to develop and commercialize innovative healthcare solutions that resonate with patients, healthcare professionals, and investors who recognize the intrinsic value of responsible, patient-centered innovation and sustainable business practices.Halozyme Therapeutics, Inc., a biopharmaceutical company at the forefront of innovative healthcare solutions, demonstrates a comprehensive commitment to ESG (Environment, Social, Governance) sustainability that encompasses a multitude of interconnected facets, reflecting its dedication to responsible corporate citizenship, ethical practices, and positive societal impact through its operations, products, and collaborations, with a focus on both immediate and long-term implications for the global community, thereby exemplifying a robust and forward-thinking approach to sustainable business practices in the biotechnology sector. Halozyme Therapeutics’ approach to stakeholder engagement is characterized by a collaborative spirit that spans patients, employees, investors, healthcare professionals, and regulatory bodies, reflecting its commitment to open dialogue, active listening, and transparent communication that ensures its strategies are informed by diverse perspectives, societal values, and the collective wisdom of its stakeholders, thereby fostering enduring relationships that contribute to positive societal impact.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$660,000,000.00

Website Traffic

Employee Rating

3.3

Customer Rating

3.9

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.